APA (7th ed.) Citation

A, C., E, G., G, L. C., F, C., V, S., L, B., . . . V, G. (2025). Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung cancer (Amsterdam, Netherlands), 209, 108799. https://doi.org/10.1016/j.lungcan.2025.108799

Chicago Style (17th ed.) Citation

A, Cortellini, et al. "Long-term Outcomes from Pembrolizumab Monotherapy in Patients with Advanced NSCLC, PD-L1 Expression ≥ 50 %, and Poor Performance Status: Transformer-based AI to Characterize Prognostic Complexity." Lung Cancer (Amsterdam, Netherlands) 209 (2025): 108799. https://doi.org/10.1016/j.lungcan.2025.108799.

MLA (9th ed.) Citation

A, Cortellini, et al. "Long-term Outcomes from Pembrolizumab Monotherapy in Patients with Advanced NSCLC, PD-L1 Expression ≥ 50 %, and Poor Performance Status: Transformer-based AI to Characterize Prognostic Complexity." Lung Cancer (Amsterdam, Netherlands), vol. 209, 2025, p. 108799, https://doi.org/10.1016/j.lungcan.2025.108799.